Baseline characteristics
| . | Number of patients with available data . | VEN monotherapy (n = 270) . | VEN combination (n = 51; 38 R, 13 obinutuzumab) . |
|---|---|---|---|
| Median age VEN start | 321 | 68 (37-91) | 66 (45-88) |
| Median prior therapies | 321 | 3 (0-12) | 2 (0-15) |
| Prior ibrutinib | 319 | 79% | 73% |
| Del17p | 323 | 43% | 44% |
| TP53 mutation | 154 | 37% | 25% |
| IGHV unmutated | 118 | 83% | 82% |
| Complex karyotype | 213 | 43% | 25% |
| . | Number of patients with available data . | VEN monotherapy (n = 270) . | VEN combination (n = 51; 38 R, 13 obinutuzumab) . |
|---|---|---|---|
| Median age VEN start | 321 | 68 (37-91) | 66 (45-88) |
| Median prior therapies | 321 | 3 (0-12) | 2 (0-15) |
| Prior ibrutinib | 319 | 79% | 73% |
| Del17p | 323 | 43% | 44% |
| TP53 mutation | 154 | 37% | 25% |
| IGHV unmutated | 118 | 83% | 82% |
| Complex karyotype | 213 | 43% | 25% |